Pfizer Says Endpoint Met in Tofacitinib OPT Study, Did Not Meet in Non-Inferiority Study
October 09, 2013 at 08:01 AM EDT
Pfizer Inc. (NYSE: PFE ) announced today top-line results from two Phase 3 clinical trials of tofacitinib, a novel, oral Janus kinase (JAK) inhibitor that is being investigated for the treatment of adults with moderate-to-severe chronic plaque psoriasis: OPT Compare (A3921080) and OPT Retreatment (A3921111). These are the first two of five studies
